1ZHANGYY.Treatment progress of gram-positive cocci infections .中国抗感染化疗杂志,2001,1(1):50-53. 被引量：1
2LUY SHUNJ ZHANGJ etal.Clinical rational analysis of monitoring results in serum concentrations of vancomycin in 340 cases .中国医院药学杂志,2007,27(5):649-650. 被引量：1
3LUXJ.Rational use of antibiotics .现代临床医学,2005,31(4):286-290. 被引量：1
4CHEN X Q, JIN Y Y, TANG G. New EditionPharmacology(新编药物学) [M]. 15th ed. Beijing: People's Medical Publishing House, 2007: 93. 被引量：1
5ZHANGXL.Clinical Drug Reference(药物临床信息参考)[M].Sichuan:Sichuan Science and Technology Press,2006:191. 被引量：1
6LEADER W G, CHANDLER M H, CASTIGLIA M. Pharmacokinetics optimization of vancomycin therapy [J]. Clin Pharmacokinet, 1995, 28(4): 327-342. 被引量：1
7TIANG WANGJL.Heterogeneity of vancomycin-resistant staphylococcus .天津医药,2005,33(10):678-680. 被引量：1
8JONES M E,VISSER M R,KLOOTWIJK M,et al.Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, lfloxacin, sparfloxacin, and trovafloxacin and nonquinoloones linozelid, quinupristin/dalfopritin, gentamicin, and vancomycin agains 被引量：1
9DREW R H,PERFECT K,SRINATH L,et al.Treatment ofmethicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopritin in patients intolerant of or failing prior therapy[J].J Antimicrob Chemother,2000,46(3):775-784. 被引量：1
10REZENDE N A,BLUMVERG H M,METZGER B Z,et al.Risk factors for methicillin-resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission[J]. Am J Med Sci,2002,323(3):117-123. 被引量：1
